Topical effects of nebivolol on wounds in diabetic rats

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 2, 2012, Pages 451-455

  Gulcan, Erim ^a   Kuçuk, Ayşegul ^b   Çayci, Kasim ^b   Tosun, Murat ^c   Emre, Habib ^d   Koral, Lokman ^e   Aktan, Yasemin ^b   Avsar, Umit ^a  

^a ATATURK UNIVERSITY   (Turkey)

^b DUMLUPINAR UNIVERSITY   (Turkey)

^c AFYON KOCATEPE UNIVERSITY   (Turkey)

^d YUZUNCU YIL UNIVERSITY   (Turkey)

^e SELCUK UNIVERSITY   (Turkey)

Author keywords

Diabetic wounds; Nebivol; Nitric oxide

Indexed keywords

LANOLIN; NEBIVOLOL; PETROLATUM; STREPTOZOCIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CREAM; DIABETIC FOOT; DIABETIC WOUND; DRUG EFFICACY; DRUG FORMULATION; HISTOPATHOLOGY; NONHUMAN; POWDER; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; TREATMENT DURATION; TREATMENT OUTCOME; WOUND; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; BENZOPYRANS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC FOOT; ETHANOLAMINES; MALE; RATS; RATS, WISTAR; VASODILATOR AGENTS; WOUND HEALING;

EID: 84865511703     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.06.017     Document Type: Article

References (14)

1. D. Altavilla, A. Saitta, and D. Cucinotta Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse Diabetes 50 2001 667 674
2. M.A. Broeders, P.A. Doevendans, and B.C. Bekkers Nebivolol:a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production Circulation 102 2000 677
3. N.E. Cameron, S.E. Eaton, and S. Tesfaye Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy Diabetologia 44 2001 1973 1988
4. I. Chow, E.V. Lemos, and T.R. Einarson Management and prevention of diabetic foot ulcers and infections: a health economic review Pharmacoeconomics 12 2008 1019
5. V. Falanga Wound healing and its impairment in the diabetic foot Lancet 336 2005 1736 1743
6. E. Gulcan Could nebivolol be an alternative drug for the treatment of diabetic foot ulcers? J. Am. Podiatr. Med. Assoc. 99 5 2009 459
7. E. Gulcan, A. Gulcan, and E. Erbilen Statins may be useful in diabetic foot ulceration treatment and prevention Med. Hypotheses 6 2007 1313
8. E. Gulcan, D. Ilhan, and S. Toker Nebivolol might be beneficial in the prevention and treatment of diabetic neuropathy Am. J. Ther. 2008 (December 23)
9. R.J. Hinchliffe, G.D. Valk, and J. Apelqvist A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes Diabetes Metab. Res. Rev. 24 Suppl. 1 2008 S119 S144
10. L. Kalinowski, L.W. Dobrucki, and M. Szczepanska- Konkel Third-generation beta blockers stimulate nitric oxiderelease from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action Circulation 107 2003 2747
11. a. Maffei, C. Vecchione, and a. Aretini Characterization of nitric oxide release by nebivolol and its metabolites Am. J. Hypertens 19 2006 579
12. R.P. Mason, R. Kubant, and R.F. Jacob Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity J. Cardiovasc. Pharmacol. 48 2006 862
13. M.J. Sheetz, and G.L. King Molecular understanding of hyperglycemia's adverse effects for diabetic complications JAMA 288 2002 2579 2588
14. S. Taddei, A. Virdis, and L. Ghiadoni Effects of antihypertensive drugs on endothelial dysfunction: clinical implications Drugs 62 2002 265